Kateřina Chramostová
Academy of Sciences of the Czech Republic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kateřina Chramostová.
Cancer Investigation | 2004
Zuzana Hoferová; Karel Souček; Jiřina Hofmanová; Michael Hofer; Kateřina Chramostová; Peter Fedoročko; Alois Kozubík
Proliferation of mouse fibrosarcoma cells G:5:113 was studied in vitro after affecting particular pathways of arachidonic acid metabolism by selected inhibitors. After 48 hours of cultivation with nonspecific lipoxygenase inhibitors, nordihydroguaiaretic acid (NDGA) and esculetin; a specific 12-lipoxygenase inhibitor, baicalein; and inhibitor of five-lipoxygenase activating protein, MK-886, markedly suppressed the number of cells and induced significant changes in cell cycle distribution in a dose-dependent manner. While proadifen, an inhibitor of cytochrome P-450-monooxygenase, applied in low concentrations, increased the cell number, at higher concentrations, it inhibited cell proliferation and significantly changed the cell cycle. Cyclooxygenase inhibitors, ibuprofen, flurbiprofen, and diclofenac suppressed cell numbers only moderately without any changes in the cell cycle. The occurrence of apoptosis was not significant for any of the selected drugs in comparison with untreated control cells. Moreover, not even one of the drugs caused the specific cleavage of poly (ADP-ribose) polymerase to the 89-kDa fragment, however, a decrease in total amount of this protein was observed after treatment with NDGA and esculetin. We conclude that the proliferation ability of fibrosarcoma cells G:5:113 in vitro depends on intact functions of 5-lipoxygenase, 12-lipoxygenase, and cytochrome P-450-monooxygenases, and that the effects of inhibitors do not include regulation of apoptosis.
Toxicology and Applied Pharmacology | 2004
Kateřina Chramostová; Jan Vondráček; Lenka Švihálková Šindlerová; Bořivoj Vojtěšek; Alois Kozubík; Miroslav Machala
Toxicological Sciences | 2004
Jan Vondráček; Miroslav Machala; Vítězslav Bryja; Kateřina Chramostová; Pavel Krčmář; Cornelia Dietrich; Aleš Hampl; Alois Kozubík
Mutation Research | 2006
Jan Vondráček; Lenka Švihálková-Šindlerová; Kateřina Pěnčíková; Pavel Krčmář; Zdeněk Andrysík; Kateřina Chramostová; Soňa Marvanová; Zuzana Valovičová; Alois Kozubík; Alena Gábelová; Miroslav Machala
Leukemia Research | 2006
Jan Vondráček; Karel Souček; Michael A. Sheard; Kateřina Chramostová; Zdeněk Andrysík; Jiřina Hofmanová; Alois Kozubík
Toxicology and Applied Pharmacology | 2006
Zdeněk Andrysík; Miroslav Machala; Kateřina Chramostová; Jiřina Hofmanová; Alois Kozubík; Jan Vondráček
Environmental Toxicology and Chemistry | 2004
Jan Vondráček; Kateřina Chramostová; Martina Plíšková; Luděk Bláha; Werner Brack; Alois Kozubík; Miroslav Machala
Drug Development Research | 2003
Zuzana Hoferová; Michal Hofer; Milan Pospíšil; Vladimír Znojil; Kateřina Chramostová
Environmental Toxicology and Chemistry | 2004
Jan Vondráček; Kateřina Chramostová; Martina Plíšková; Luděk Bláha; Werner Brack; Alois Kozubík; Miroslav Machala
Cancer Investigation | 2004
Zuzana Hoferová; Karel Souček; Jiřina Hofmanová; Michal Hofer; Kateřina Chramostová; Peter Fedoročko; Alois Kozubík